News
-

Kisspeptin Benefits: What Human Studies Found
In people, kisspeptin has done two things reliably: switched on the reproductive hormone system, and changed how the brain handles sexual cues. Nearly all of it was measured over hours, in a hospital.
-

KLOW Peptide Stack: Four Peptides in One Vial
A “stack” just means taking more than one peptide at a time. KLOW is one that comes already mixed — four peptides in a single prescribed vial, so there is nothing for you to assemble.
-

Sermorelin Cost: What You’re Really Paying For
In three current public telehealth listings, recurring sermorelin plans run from $149 to $279 a month. The useful comparison is not just the vial price, but what the plan includes and who is accountable for it.
-

Tesamorelin Half-Life Is Measured in Minutes
Tesamorelin leaves the bloodstream quickly, but the signal it starts can last much longer. That difference explains why trials used it once daily and why providers follow IGF-1 instead of watching the clock.
-

Tirzepatide Pills Don't Exist. Here's What Does
There is no oral tirzepatide, either as a brand product or a validated compounded pill. Real GLP-1 tablets contain semaglutide or orforglipron, which are different medicines.
-

Zepbound vs Wegovy: Two Drugs, Not Two Brands
They get compared like two versions of one medicine. They are not — different molecules, different makers, and different lists of what each one is cleared to treat.
-

Is Sermorelin FDA Approved? Not Since 2009
Geref, the only sermorelin product the United States ever approved, left the market in 2008 and its approvals were withdrawn in 2009 — not over safety. Here is what that means for a prescription today.
-

Kisspeptin for Men: What the Studies Really Show
Kisspeptin may affect reproductive hormones and sexual response in men. The evidence is promising but small, and it does not establish a standard dose or long-term treatment plan.
-

Semaglutide and Heart Health: What Studies Show
Semaglutide has been linked to fewer major cardiovascular events in a specific high-risk group, and to better symptoms in one type of heart failure. The numbers are meaningful, but they do not apply to every heart or every formulation.
-

Semaglutide and Vision: What's Real, What's Rare
Most people never have an eye problem because of semaglutide. Two things do come up, though, and they get mixed together constantly — so here is what each one actually is.
-

Semaglutide for Heart Failure Now Has ESC Support
Europe's 2026 heart-failure guideline now says semaglutide or tirzepatide should be considered for symptomatic patients with obesity and an ejection fraction of at least 45%. The recommendation is about symptoms, walking capacity, and quality of life—not proof that semaglutide prevents death.
-

Tirzepatide Diabetic Retinopathy: Who It's For
The tirzepatide diabetic retinopathy warning was revised on both U.S. labels in August 2026. It asks for eye monitoring in people who already have the condition — not a finding that the medicine harms eyes.
-

Tirzepatide Heart Benefits: Who the Label Covers
In August 2026 the brand-name version of tirzepatide gained a new use on its label: lowering the risk of heart attack, stroke and cardiac death in adults with type 2 diabetes. Here is what that covers, and what it doesn't.
-

Tirzepatide vs Ozempic: What You're Comparing
Ozempic is a brand of semaglutide, approved for type 2 diabetes. Tirzepatide is a different molecule with its own brands — so the comparison most people want is between two drugs, not a drug and a label.
-

What Is Sermorelin Used For? A Plain Answer
Geref received approvals in 1990 for testing pituitary growth hormone release and in 1997 for children with growth failure from growth hormone deficiency. Adults are prescribed it today for sleep, body composition and recovery — uses that rest on a handful of small studies.
-

CJC-1295 Ipamorelin for Women: Evidence and Limits
CJC-1295 with ipamorelin may stimulate the growth-hormone axis, but no clinical trial has tested the combination specifically in women. Perimenopause, estrogen route and the limits of body-composition and sleep evidence all matter to the prescribing decision.
-

Does CJC-1295 Ipamorelin Work? Evidence Review
The combination has no clinical trial of its own. Separate studies show that CJC-1295 and ipamorelin can raise growth hormone signals, but they do not establish predictable sleep, recovery, muscle, or fat-loss results from the blend.
-

Does Sermorelin Cause Hair Loss? Evidence Review
Current evidence does not identify hair loss as a sermorelin side effect. Growth hormone and IGF-1 affect follicles, but that biology cannot explain why one person starts shedding.
-

GLP-1 Patches: Do They Work?
GLP-1 patches sold online are usually supplement stickers, not semaglutide or tirzepatide. Ordinary patches cannot move these large peptide drugs across intact skin in a predictable dose.
-

Kisspeptin Side Effects: What Human Trials Found
Short human trials suggest few systemic effects, while injection-site stinging can happen and repeated exposure can blunt the hormone response. The major unknown is long-term safety.
Page 17 of 27 · 528 articles